BRIEF—Gilead pays $725 million to in-license Arcus candidates

Gilead Sciences has completed the process of exercising an option on three programs in Arcus Biosciences' clinical-stage portfolio.

The options relate to the anti-TIGIT molecules domvanalimab and AB308, as well as the clinical candidates etrumadenant and quemliclustat.

The closing of the transaction triggers option payments totaling $725 million from Gilead to Arcus, expected to be paid at the start of 2022.

The parties will co-develop and share the global costs related to these clinical programs.

If the optioned molecules achieve regulatory approval, Gilead and Arcus will co-commercialize and equally share profits in the USA.

Outside America, Gilead holds exclusive commercialization rights, subject to any rights of Arcus’ existing collaboration partners, and Gilead would pay Arcus tiered royalties on net sales of each optioned product.